+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical Drug Delivery Market By Route of Administration, By Application: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 236 Pages
  • June 2023
  • Region: Global
  • Allied Market Research
  • ID: 5031434
Description Jump to:
The pharmaceutical drug delivery market was valued for $1,498.72 billion in 2022 and is estimated to reach $2,307.27 billion by 2032, exhibiting a CAGR of 4.4% from 2023 to 2032. Pharmaceutical drug delivery is defined as a process of administering medications or therapeutic substances to patients to achieve the desired therapeutic effect. It involves designing and development of various methods, systems, and technologies that enable safe and effective delivery of drugs to specific target sites within the body. Drug delivery systems are developed to maximize the effectiveness of medications, reduce the potential adverse effects, enhance bioavailability, and improve patient compliance. The common drug delivery methods are oral delivery, injectable delivery, transdermal delivery, topical delivery, targeted delivery, and others. The pharmaceutical drug delivery market growth is driven by an Increase in the number of people suffering from chronic diseases, rise in prevalence of geriatric population, and advancement in R&D activities in pharmaceutical industry.

Chronic diseases, such as cardiovascular disorders, diabetes, cancer, and respiratory diseases, are characterized by long-term medication treatment. These conditions require regular administration of drugs to control symptoms, slow disease progression, or maintain quality of life. This has Increased the demand for effective drug delivery systems, thereby driving the market growth. According to International Diabetes Federation (IDF), in 2021, it was estimated that about 3 in 4 adults with diabetes live in low and middle Income countries and approximately 206 million people were diagnosed with diabetes in western pacific.

For instance, in May 2022, U.S. Food and Drug Administration (FDA), approved new injectable delivery product, Mounjaro to treat type 2 diabetes. Thus, the rise in prevalence of diabetes has led to the development of advanced insulin delivery systems, which are highly effective to treat diabetes. In addition, growth in prevalence of age-related diseases such as cardiovascular disorders, arthritis, neurodegenerative diseases, and osteoporosis have created a significant demand for effective drug delivery.

For instance, in January 2023, Biogen Inc., one of the global leader in pharmaceutical industry, received U.S. Food and Drug Administration (FDA) approval for LEQEMBI to treat Alzheimer’s disease. LEQEMBI is a monoclonal antibody directed intravenous drug delivery medication that effectively treats Alzheimer’s disease. Thus, development of new targeted drug delivery and controlled release formulation further contribute toward the market growth. However, stringent regulatory requirements can Increase the time, cost, and complexity of new drug delivery technologies and restrain market growth. Furthermore, high costs associated with research and development of new drug delivery negatively impact market growth.

On the other hand, an Increase in demand for advanced drug delivery systems is expected to create lucrative opportunities for market growth during the forecast period. This is attributed to the Increase in prevalence of chronic diseases, enhanced treatment outcomes, and availability of favorable reimbursement policies for the development of advanced drug delivery systems.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. As per application, the market is categorized into cancer, diabetes, cardiovascular diseases, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global pharmaceutical drug delivery market are Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., Sanofi. Key players operating in the market have adopted product launch and product approval as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical drug delivery market analysis from 2022 to 2032 to identify the prevailing pharmaceutical drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report Includes the analysis of the regional as well as global pharmaceutical drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Route of Administration

  • Topical drug delivery
  • Other drug delivery
  • Oral drug delivery
  • Nasal drug delivery
  • Ocular drug delivery

By Application

  • Cancer
  • Diabetes
  • Cardiovascular Diseases
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Amgen Inc.
  • Bayer AG
  • Cipla Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of various chronic diseases
3.4.1.2. Technological advancement in drug delivery systems
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for the approval of pharmaceutical drug delivery
3.4.3. Opportunities
3.4.3.1. Increase in demand for advanced delivery systems
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral drug delivery
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Nasal drug delivery
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Ocular drug delivery
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Topical drug delivery
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Other drug delivery
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Diabetes
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Cardiovascular Diseases
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Route of Administration
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Route of Administration
6.2.4.1.3. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Route of Administration
6.2.4.2.3. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Route of Administration
6.2.4.3.3. Market size and forecast, by Application
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Route of Administration
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Route of Administration
6.3.4.1.3. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Route of Administration
6.3.4.2.3. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Route of Administration
6.3.4.3.3. Market size and forecast, by Application
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Route of Administration
6.3.4.4.3. Market size and forecast, by Application
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Route of Administration
6.3.4.5.3. Market size and forecast, by Application
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Route of Administration
6.3.4.6.3. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Route of Administration
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Route of Administration
6.4.4.1.3. Market size and forecast, by Application
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Route of Administration
6.4.4.2.3. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Route of Administration
6.4.4.3.3. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Route of Administration
6.4.4.4.3. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Route of Administration
6.4.4.5.3. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Route of Administration
6.4.4.6.3. Market size and forecast, by Application
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Route of Administration
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Route of Administration
6.5.4.1.3. Market size and forecast, by Application
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Route of Administration
6.5.4.2.3. Market size and forecast, by Application
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Route of Administration
6.5.4.3.3. Market size and forecast, by Application
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Route of Administration
6.5.4.4.3. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. F. Hoffmann-La Roche Ltd.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. GlaxoSmithKline plc
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Johnson & Johnson
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Merck & Co., Inc.
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Novartis AG
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Pfizer Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Sanofi S.A.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. Bayer AG
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Cipla Ltd
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Amgen Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
List of Tables
TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 02. PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 03. PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 04. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 05. PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 06. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY REGION, 2022-2032 ($BILLION)
TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2022-2032 ($BILLION)
TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2022-2032 ($BILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($BILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($BILLION)
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 14. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 15. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 16. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 17. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 18. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 19. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 20. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 23. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 24. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 26. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 27. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 28. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 29. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 30. UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 31. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 32. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 33. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 34. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 35. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 36. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 37. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 38. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 39. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 40. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 41. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 42. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 43. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 44. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 45. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 46. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 47. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 48. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 49. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 50. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 51. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 52. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 53. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 54. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($BILLION)
TABLE 55. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 56. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 57. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 58. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 59. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 60. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 61. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($BILLION)
TABLE 62. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022-2032 ($BILLION)
TABLE 63. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 64. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 65. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 66. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 67. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 68. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 69. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 70. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 71. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 72. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 73. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 74. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 75. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 76. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 77. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 78. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 79. NOVARTIS AG: KEY EXECUTIVES
TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 83. NOVARTIS AG: KEY STRATERGIES
TABLE 84. PFIZER INC.: KEY EXECUTIVES
TABLE 85. PFIZER INC.: COMPANY SNAPSHOT
TABLE 86. PFIZER INC.: PRODUCT SEGMENTS
TABLE 87. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 88. SANOFI S.A.: KEY EXECUTIVES
TABLE 89. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 90. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 91. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 92. BAYER AG: KEY EXECUTIVES
TABLE 93. BAYER AG: COMPANY SNAPSHOT
TABLE 94. BAYER AG: PRODUCT SEGMENTS
TABLE 95. BAYER AG: PRODUCT PORTFOLIO
TABLE 96. CIPLA LTD: KEY EXECUTIVES
TABLE 97. CIPLA LTD: COMPANY SNAPSHOT
TABLE 98. CIPLA LTD: PRODUCT SEGMENTS
TABLE 99. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 100. AMGEN INC.: KEY EXECUTIVES
TABLE 101. AMGEN INC.: COMPANY SNAPSHOT
TABLE 102. AMGEN INC.: PRODUCT SEGMENTS
TABLE 103. AMGEN INC.: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN PHARMACEUTICAL DRUG DELIVERY MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 10. PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR ORAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OCULAR DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR TOPICAL DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER DRUG DELIVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. PHARMACEUTICAL DRUG DELIVERY MARKET BY REGION, 2022
FIGURE 22. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 23. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 24. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 25. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 28. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 29. SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 30. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 31. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 32. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 33. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 34. AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 35. SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 36. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 37. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 38. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 39. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 40. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2022-2032 ($BILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 72. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

Executive Summary

According to a new report, titled, 'Pharmaceutical Drug Delivery Market,' The pharmaceutical drug delivery market was valued at $1,498.72 billion in 2022, and is estimated to reach $2307.27 billion by 2032, growing at a CAGR of 4.4% from 2023 to 2032.

Pharmaceutical drug delivery is a process of delivering medications or therapeutic substances to patients in order to achieve the desired therapeutic effect at the site of action. It involves the design and development of various methods and technologies to safely and effectively deliver drugs to specific target sites within the body. The primary aim of drug delivery is to increase the effectiveness of therapeutic drug, minimize potential adverse effects, increase bioavailability, and improve patient adherence. Common routes of drug delivery include oral, injectable, transdermal, topical, targeted, and other specialized approaches. The oral route is the most convenient route of administration for patients as it involves swallowing a tablet, capsule, or liquid medication, which is generally easier and more acceptable than other routes such as injections or inhalations.

Key factors driving the growth of the pharmaceutical drug delivery market include increase in prevalence of diabetes, cancer, and hypertension; surge in geriatric population; and rise in development of advanced drug delivery products. Chronic diseases, such as diabetes, cardiovascular diseases, respiratory disorders, and cancer, are becoming more common due to factors like aging populations and changing lifestyles. These diseases require long-term medication management, which necessitates the development of effective drug delivery systems. Pharmaceutical drug delivery aims to optimize the administration of medications to achieve desired therapeutic effects. For instance, targeted drug delivery delivers the medication directly to tumor cells and improves cancer treatment outcomes while minimizing damage to healthy tissues.

Furthermore, the rise in chronic diseases has led to an increased demand for drug delivery technologies that enhance patient compliance and convenience. For instance, oral controlled-release formulations provide convenient and patient-friendly options for medication administration which improves adherence and quality of life for individuals managing chronic conditions. In addition, pharmaceutical companies are investing in research and development to innovate drug delivery approaches that cater to the specific needs of chronic disease management. This includes the development of novel drug formulations and technologies that enhance drug stability, improve bioavailability, and provide sustained release of medications.

Furthermore, emergence of new drug delivery methods such as liposomal drug delivery, nanoparticle-based drug delivery, and controlled-release drug delivery further boosts the market growth. Liposomes are small vesicles composed of lipid bilayers that encapsulate drugs within their lipid membrane. These drug-loaded liposomes can protect the drug from degradation, improve its solubility, and enhance its stability. Liposomes can also be engineered to target specific cells or tissues which allows site-specific drug delivery. For instance, liposomal doxorubicin (Doxil) is a liposome-encapsulated formulation of the chemotherapeutic drug doxorubicin, which has improved therapeutic efficacy and reduced side effects as compared to conventional doxorubicin formulations. Similarly, Abraxane is a nanoparticle-based formulation of the anticancer drug paclitaxel. The nanoparticles improve paclitaxel's solubility and allow for targeted delivery to tumor cells, resulting in enhanced therapeutic efficacy.

Furthermore, the shift toward personalized medicine is the key factor driving the demand for advanced drug delivery that can deliver targeted therapies, customized dosages, and controlled release formulation also contributes toward the market. Moreover, the increase in demand for advanced drug delivery systems, which improve therapeutic outcomes and enhance patient convenience are expected to drive the market growth. Long acting injectables offer sustained release of medications and reduced dosing frequency. This has led to increased demand for long-acting injectables over the short-acting injectables. Additionally, the rise in the number of pharmaceutical companies which are developing advanced drug delivery systems to enhance medication effectiveness and safety is creating new opportunities for market growth during the forecast period.

The pharmaceutical drug delivery market is segmented on the basis of route of administration, application, and region. On the basis of route of administration, the market is classified into oral drug delivery, nasal drug delivery, ocular drug delivery, topical drug delivery, and other drug delivery. On the basis of application, the market is categorized into cancer, diabetes, cardiovascular, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players profiled in the pharmaceutical drug delivery market include Bayer AG, Cipla Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Amgen Inc., Pfizer Inc., and Sanofi.

Key Market Insights

  • By route of administration, the other drug delivery segment was the highest revenue contributor to the market in 2022 and is estimated to reach $963.42 billion by 2032.
  • On the basis of application, the others segment dominated the global market and it is expected to register highest CAGR during the forecast period.
  • Based on region, North America garnered the largest revenue share in 2022. However Asia-Pacific is anticipated to grow at the highest CAGR of 5.1% during the forecast period.

Companies Mentioned

  • Amgen Inc.
  • Bayer AG
  • Cipla Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Drug Delivery Market - Forecasts from 2024 to 2029 - Product Image

Drug Delivery Market - Forecasts from 2024 to 2029

  • Report
  • 132 Pages
  • Global
From
North America Drug Delivery Market - Forecasts from 2023 to 2028 - Product Image

North America Drug Delivery Market - Forecasts from 2023 to 2028

  • Report
  • 92 Pages
  • North America
From
Pharmaceutical Drug Delivery Market by Route of Administration, by Application, Regional Outlook - Global Forecast up to 2030 - Product Image

Pharmaceutical Drug Delivery Market by Route of Administration, by Application, Regional Outlook - Global Forecast up to 2030

  • Report
  • 120 Pages
  • Global
From
Pharmaceutical Drug Delivery Market Report by Route of Administration, Application, End User, and Region 2024-2032 - Product Image

Pharmaceutical Drug Delivery Market Report by Route of Administration, Application, End User, and Region 2024-2032

  • Report
  • 144 Pages
  • Global
From
Topical Drug Delivery Market Market By Product, By Route Of Administration, Regional Outlook - Global Forecast up to 2030 - Product Image

Topical Drug Delivery Market Market By Product, By Route Of Administration, Regional Outlook - Global Forecast up to 2030

  • Report
  • 116 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.